Virus Fighter
Each year, more than five million people in the United States are infected with human papillomavirus-some strains of which can cause genital warts and cancers-during sex. One of the most common causes of sexually transmitted disease, the virus is highly contagious, and so far, nobody has come up with a way to fight it directly. Doctors can remove the warts with chemicals, lasers or other means, but the virus isn’t affected. Now Quebec-based Origenix Technologies is testing a drug the company believes will combat both the warts and the virus by blocking the microbe’s ability to replicate.
The drug is a specially modified DNA molecule that interferes with one of the genes the virus uses to replicate itself once it infects a human cell. Origenix has completed animal testing of a cream containing the drug, says executive vice president Anthony Payne. The company hopes to begin U.S. clinical trials this summer.
Keep Reading
Most Popular
Large language models can do jaw-dropping things. But nobody knows exactly why.
And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.
The problem with plug-in hybrids? Their drivers.
Plug-in hybrids are often sold as a transition to EVs, but new data from Europe shows we’re still underestimating the emissions they produce.
Google DeepMind’s new generative model makes Super Mario–like games from scratch
Genie learns how to control games by watching hours and hours of video. It could help train next-gen robots too.
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.